These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 28636052)

  • 1. Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).
    Robb CM; Contreras JI; Kour S; Taylor MA; Abid M; Sonawane YA; Zahid M; Murry DJ; Natarajan A; Rana S
    Chem Commun (Camb); 2017 Jul; 53(54):7577-7580. PubMed ID: 28636052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
    King HM; Rana S; Kubica SP; Mallareddy JR; Kizhake S; Ezell EL; Zahid M; Naldrett MJ; Alvarez S; Law HC; Woods NT; Natarajan A
    Bioorg Med Chem Lett; 2021 Jul; 43():128061. PubMed ID: 33895280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.
    Bian J; Ren J; Li Y; Wang J; Xu X; Feng Y; Tang H; Wang Y; Li Z
    Bioorg Chem; 2018 Dec; 81():373-381. PubMed ID: 30196207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of selective mono or dual PROTAC degrader probe of CDK isoforms.
    Zhou F; Chen L; Cao C; Yu J; Luo X; Zhou P; Zhao L; Du W; Cheng J; Xie Y; Chen Y
    Eur J Med Chem; 2020 Feb; 187():111952. PubMed ID: 31846828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer.
    Li J; Liu T; Song Y; Wang M; Liu L; Zhu H; Li Q; Lin J; Jiang H; Chen K; Zhao K; Wang M; Zhou H; Lin H; Luo C
    J Med Chem; 2022 Aug; 65(16):11034-11057. PubMed ID: 35925880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals).
    Schiedel M; Herp D; Hammelmann S; Swyter S; Lehotzky A; Robaa D; Oláh J; Ovádi J; Sippl W; Jung M
    J Med Chem; 2018 Jan; 61(2):482-491. PubMed ID: 28379698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
    Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
    Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategy.
    Mallareddy JR; Singh S; Boghean L; Natarajan A
    Future Med Chem; 2022 Jan; 14(3):131-134. PubMed ID: 34814708
    [No Abstract]   [Full Text] [Related]  

  • 9. First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo.
    Wei M; Zhao R; Cao Y; Wei Y; Li M; Dong Z; Liu Y; Ruan H; Li Y; Cao S; Tang Z; Zhou Y; Song W; Wang Y; Wang J; Yang G; Yang C
    Eur J Med Chem; 2021 Jan; 209():112903. PubMed ID: 33256948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.
    Xiao L; Liu Y; Chen H; Shen L
    Cancer Biol Ther; 2023 Dec; 24(1):2219470. PubMed ID: 37272701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
    Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
    Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CDK9 in Cancer: An Integrated Approach of Combining In Silico Screening with Experimental Validation for Novel Degraders.
    Koirala M; DiPaola M
    Curr Issues Mol Biol; 2024 Feb; 46(3):1713-1730. PubMed ID: 38534727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring and deciphering protein degradation pathways inside cells.
    Daniels DL; Riching KM; Urh M
    Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription Elongation Factor P-TEFb Is Involved in IL-17F Signaling in Airway Smooth Muscle Cells.
    Nakajima M; Kawaguchi M; Matsuyama M; Ota K; Fujita J; Matsukura S; Huang SK; Morishima Y; Ishii Y; Satoh H; Sakamoto T; Hizawa N
    Int Arch Allergy Immunol; 2018; 176(2):83-90. PubMed ID: 29649811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK9 inhibitors in cancer research.
    Huang Z; Wang T; Wang C; Fan Y
    RSC Med Chem; 2022 Jun; 13(6):688-710. PubMed ID: 35814933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis.
    Iankova I; Petersen RK; Annicotte JS; Chavey C; Hansen JB; Kratchmarova I; Sarruf D; Benkirane M; Kristiansen K; Fajas L
    Mol Endocrinol; 2006 Jul; 20(7):1494-505. PubMed ID: 16484339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase.
    Degorce SL; Tavana O; Banks E; Crafter C; Gingipalli L; Kouvchinov D; Mao Y; Pachl F; Solanki A; Valge-Archer V; Yang B; Edmondson SD
    J Med Chem; 2020 Sep; 63(18):10460-10473. PubMed ID: 32803978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional inactivation of Cdk9 through oligomerization chain reaction.
    Napolitano G; Mazzocco A; Fraldi A; Majello B; Lania L
    Oncogene; 2003 Jul; 22(31):4882-8. PubMed ID: 12894230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical interaction between pRb and cdk9/cyclinT2 complex.
    Simone C; Bagella L; Bellan C; Giordano A
    Oncogene; 2002 Jun; 21(26):4158-65. PubMed ID: 12037672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional regulation by targeted recruitment of cyclin-dependent CDK9 kinase in vivo.
    Majello B; Napolitano G; Giordano A; Lania L
    Oncogene; 1999 Aug; 18(32):4598-605. PubMed ID: 10467404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.